What question did this study set out to answer?

The study aims to characterize T-cell responses to SARS-CoV-2 vaccination in individuals with Down syndrome across different ages.

June 3, 2026Open Access

T-cell responses to primary SARS-CoV-2 vaccination in Down syndrome – From childhood to adulthood

Key Points

The study aims to characterize T-cell responses to SARS-CoV-2 vaccination in individuals with Down syndrome across different ages.
Evaluated T-cell abundance in participants aged 3-74 years with Down syndrome (N=40)
Measured interferon-gamma (IFNγ) production post spike antigen re-stimulation (N=55)
Analyzed age-dependent vaccine-induced cellular responses.
No significant difference in the re-activation of SARS-CoV-2-specific CD4 T-cells across ages after vaccination.

Abstract

Down syndrome (DS) is the most common genetic disorder worldwide and associated with high morbidity and mortality rates during the COVID-19 pandemic. For safety reasons, SARS-CoV-2 vaccine schedules and dosages were age-dependent, with children <12 years (y) receiving a lower dose than adolescents and adults. While we previously reported age-dependent antibody responses after SARS-CoV-2 vaccination in children with DS, cellular vaccine responses in this population remain insufficiently characterized. We evaluated vaccine-induced T-cell responses in children with DS following primary mRNA SARS-CoV-2 vaccination. We measured SARS-CoV-2-specific T-cell abundance (N = 40) and their interferon-gamma (IFNγ) production (N = 55) after spike antigen re-stimulation in participants aged 3-74 y. We found no significant difference in the re-activation of SARS-CoV-2-specific CD4

T-cell responses to primary SARS-CoV-2 vaccination in Down syndrome – From childhood to adulthood

Key Points

Abstract

Cite This Study